CURRICULUM VITAE

 

PERSONAL INFORMATION

Name:  Michael E. Jung

Date and Place of Birth:  May 14, 1947 in New Orleans, Louisiana

Marital Status:  Married, wife Alice

Mailing Address:    Department of Chemistry

                               University of California

                               Los Angeles, CA 90095-1569

Telephone:  (310) 825-7954              FAX: (310) 206-3722

email: jung@chem.ucla.edu

 

EDUCATIONAL BACKGROUND

Distinguished Professor, UCLA, 2004 - present

Professor Further Above Scale, UCLA, 2002 - 2004

Professor Above Scale, UCLA, 1998 - 2002

Professor VIII, UCLA, 1996 - 1998

Professor VII, UCLA, 1994 - 1996

Professor VI, UCLA, 1992 - 1994

Professor V, UCLA, 1990 - 1992

Professor IV, UCLA, 1988 - 1990

Professor III, UCLA, 1987 - 1988

Professor II, UCLA, 1985 - 1987

Professor I, UCLA, 1983 - 1985

Associate Professor III, UCLA, 1981 - 1983

Associate Professor I, UCLA, 1979 - 1981

Assistant Professor IV, UCLA, 1977 - 1979

Assistant Professor III, UCLA, 1976 - 1977

Assistant Professor II, UCLA, 1974 - 1976

NATO Postdoctoral Fellowship, Eidgenössische Technische Hochschule, Zürich, Switzerland, 1973 - 1974; Albert Eschenmoser, advisor

Ph.D., Columbia University, New York, New York, 1973; Gilbert Stork, advisor

B.A., Summa cum laude, Rice University, Houston, Texas, 1969; Richard Turner, advisor

 

PROFESSIONAL AFFILIATION

 

American Chemical Society, 1969 - present

The Chemical Society, 1971 - present

Phi Lambda Upsilon, 1968 - present

UCLA Cancer Center, 1975 - present

Division of Organic Chemistry, ACS, 1975 - present

Division of Medicinal Chemistry, ACS, 1975 - present

Sigma Xi, 1977 - present

American Men and Women of Science, Chemistry, 1977 - present

American Association for the Advancement of Science, 1979 - present

Molecular Biology Institute, UCLA, 2004 - present

California NanoSystems Institute (CNSI), UCLA, 2006 - present.

Director, UCLA Biosciences Synthetic Chemistry Core Facility, 2006 - present.

 

COWORKERS

 

Current:  9 graduate students, 7 postdoctoral associates

Former:  79 PhD's granted, 7 MS's granted, 99 postdoctoral associates, 40 undergraduates, 21 research associates and technicians

 


HONORS AND AWARDS

Professional - University of California


2009        Plenary Lecturer, ZaCh Systems Symposium on Organic Synthesis, Paris
2009        Plenary Lecturer, Center for Cancer Research Eminent Lecture Series, National Cancer
                    
Institute, Bethesda, MD
2008        Plenary Lecturer, Organic Synthesis Symposium, 43rd Mexican Chemical Society
                     National Meeting, Tijuana, Mexico
2008        Plenary Lecturer, Symposium in honor of Victor Marquez, American Chemical Society
                     National Meeting, Philadelphia, PA

2008        Plenary Lecturer, Chemical Insights into Biological Processes, Center for Cancer Research, 

                    National Cancer Institute, Frederick, MD

2008        Plenary Lecturer, Symposium on Organic Synthesis, 91st National Meeting

                     of the Canadian Society for Chemistry, Edmonton, Canada
2007        Wolfrom Award Symposium in honor of Muthiah Manoharan, 234th ACS National
                     Meeting, Boston, MA

2006        Boehringer-Ingelheim Lecturer, University of British Columbia, Vancouver

2004        Plenary Lecturer, Ischia Advanced School of Organic Chemistry, Ischia, Italy

2004        Bristol-Myers Squibb Lecturer, University of Puerto Rico, Rio Piedras, PR

2003        Invited Professor, Université Pierre et Marie Curie, Paris

2002        Auspex Horizon Award, Auspex Pharmaceutical Co., Inc., San Diego, CA

2002        Plenary Lecturer, 60th Anniversary International Symposium

                     on Organic Synthesis, Tokyo, Japan

2001        Plenary Lecturer, First International Symposium on Asymmetric Synthesis

                     Universidad Nacional Autonoma de Mexico (UNAM), Mexico City

1999        Plenary Lecturer, Japan Pharmaceutical Society, Tokushima, Japan

1999        Plenary Lecturer, Japan Chemical Society, Tokyo, Japan

1998        Plenary Lecturer, 21st Gulf Coast Chemistry Conference, Pensacola, FL

1998        Invited Lecturer, XIII International Round Table on Nucleosides, Nucleotides

                    and Their Biological Applications, Montpellier, France

1998        Invited Lecturer, 19th International Carbohydrate Symposium, La Jolla, CA

1998        Plenary Lecturer, Western Switzerland Lecture Tour

1998        Plenary Speaker, Spring Meeting, French Chemical Society, Paris 

1998        Plenary Lecturer, Robert A. Welch Foundation

1997        Plenary Speaker, 2nd AFMC International Medicinal Chemistry Symposium

                    (AIMECS 97), Seoul

1997        Invited Lecturer, 16th International Congress of Heterocyclic Chemistry,

                    Montana State University, Bozeman, MT 

1995        American Chemical Society Arthur C. Cope Scholar Award

1995        Plenary Lecturer, Gordon Conference on Purines, Pyrimidines,

                    and Other Related Substances 

1995        Plenary Lecturer, 5th French American Chemical Society (FACS) Conference 

1992        Hanson-Dow Teaching Award, UCLA

1991        Herbert Newby McCoy Award Recipient, UCLA

1991        Fujii-Ohtsuka Professor, University of Tokushima, Tokushima, Japan

1988        Plenary Lecturer, 3rd Nozaki Conference, Sagamihara, Japan

1987        Glenn T. Seaborg Award Recipient

1987        Plenary Lecturer, Gordon Conference on Natural Products Chemistry

1987        Plenary Lecturer, Gordon Conference on Organic Reactions and Processes

1986        Inaugural UCLA Gold Shield Faculty Prize

1985        Plenary Lecturer, 9th Oxford Symposium on Organic Synthesis, Oxford

1982        Plenary Lecturer, 4th International Conference on Organic Synthesis, Tokyo

1981        Invited Participant, Twelfth Annual Workshop on Organic Synthesis in
                    Natural Products Chemistry, Pingree Park, Colorado
1981        Plenary Lecturer, French Chemical Society Meeting, Paris (Spring)
1980        Fulbright-Hays Grant, U.S. Research Scholar Award
1980        American Cyanamid Young Researcher Award
1980        Plenary Lecturer, Gordon Conference on Organometallic Chemistry
1979        Alfred P. Sloan Foundation Research Fellow
1979        Camille and Henry Dreyfus Teacher-Scholar Grantee

1977        Eli Lilly Grantee
1978        University Distinguished Teaching Award

1978        Invited Speaker, Symposium for Creative Work in Synthetic Organic

                    Chemistry, 175th ACS National Meeting, Anaheim

1978        Plenary Lecturer, 5th Annual Conference on Organosilicon Chemistry

1977        Invited Participant, Eight Annual Workshop on Organic Synthesis in Natural

                    Products Chemistry, Dartmouth College Minary Conference Center, NH

1975        UCLA Summer Faculty Fellow

Postgraduate - Eidgenössische Technische Hochschule


1973        NATO Postdoctoral Fellow


Graduate - Columbia University

1973        Hammett Award for Research  

1969-73   National Studies Foundation Predoctoral Fellow


Undergraduate - Rice University

1968        Phi Beta Kappa

1967-69   ARCS Foundation Scholar 

1967-68   Blanche White Honor Scholar

1966-67   William Marsh Rice Scholar

1965-66   University Prize Scholar

 


FOUNDER

 

Aragon Pharmaceuticals, Inc., La Jolla, CA, 2009 - present


MEMBERSHIP ON SCIENTIFIC ADVISORY BOARDS

 

Auspex Pharmaceuticals, Inc., Vista, CA, 2004 - present
Trius Pharmaceuticals (formerly Rx3 Pharmaceuticals), San Diego, CA, 2006 - present
Neurocrine Biosciences, Inc., La Jolla, CA, 2003 - present

Medivation, Inc., San Francisco, CA, 2006 - 2009

Encore Pharmaceutical, Inc., Loma Linda, CA, 1998 - 2002

 

CONSULTANTSHIPS

 

Wyeth Research, Inc. (formerly Wyeth-Ayerst, American Home Products (AHP), American
     Cyanamid Company, Lederle Laboratories), Pearl River, NY, 1988 - present

Wyeth Research, Inc. (formerly AHP Medical Research Div.), Princeton, NJ, 1995 - present

Wyeth Research, Inc., Collegeville, PA (formerly Radnor, PA), 1998 - present

Wyeth Research, Inc. (formerly Genetics Institute), Cambridge, MA, 2001 - present

Isis Pharmaceuticals, Carlsbad, CA, 1995 - present

ORIL, S.A., Bolbec, France, 1996 - present

Gilead Science Process Chemistry, Foster City, CA, 1996 - present

Gilead Science Medicinal Chemistry, Foster City, CA, 1999 - present

Institut de Recherche Servier, Servier Pharmaceutical Inc., Suresnes, France, 2000 - present

DuPont Crop Protection, Newark, DE, 2002 - present

Alnylam, Inc., Cambridge, MA, CA, 2003 - present

Cylene Pharmaceuticals, San Diego, CA, 2003 - present.

Celgene Pharmaceutical, Inc., San Diego, CA, 2003 - present

Auspex Pharmaceuticals, Inc., Vista, CA, 2004 - present

ArQule Pharmaceutical Inc., Woburn, MA, 2005 - present

Abraxis BioSciences, Inc., Santa Monica, CA, 2005 - present

Trius Pharmaceuticals (formerly Rx3 Pharmaceuticals), San Diego, CA 2006 - present

ZaCh System, Inc. (formerly PPG-Sipsy), Angers, France 2007 - present

Prestwick Chemicals, Inc., Strasbourg, France 2007 - present

GlaxoSmithKline (GSK) Pharmaceuticals, Inc., Collegeville, PA 2008 - present

GlaxoSmithKline (GSK) Pharmaceuticals, Inc., Res. Triangle Park, NC, 2008 - present

Vertex Pharmaceutical, San Diego, CA, 2008 - present

Orphagen Pharmaceuticals, San Diego, CA 2008 - present
CalciMedica, Inc., San Diego, CA 2008 - present

 

 


CURRENT RESEARCH

 

      The majority of the research personnel in my group are currently engaged in three general fields of interest:  the development of new synthetic methods, the total synthesis of biologically active natural products, and medicinal chemistry. We are pursuing the total synthesis of potent antiviral agents, e.g., modified nucleosides and betulinic acid derivatives, several promising antitumor agents, e.g., tedanolide and 13-deoxytedanolide, eleutherobin, dichlorolissoclimide, haterumaimide E, the auripyrones, and laurenediterpenol. The use of epoxide rearrangements in synthesis, e.g., the non-aldol aldol process, and others, is under investigation as well, especially for the synthesis of new antibiotics of the erythromycin class. We are also studying the use of various reactions (e.g., Diels-Alder reactions, bridged Robinson annulation, [3,3] rearrangements) for the synthesis of biologically active molecules, e.g., the acetylcholinesterase inhibitors, the arisugacins; the immunosuppressive agent brasilicardin A; the antibacterial agent mycosporulone; and multiple drug resistance reversing agents such as welwitindolinone C. In particular, we are developing the mixed Lewis acid system, 5:1 AlBr3:AlMe3, in a variety of reactions, e.g., cycloadditions, nucleophilic additions, etc. We are developing new processes for the efficient synthesis of various oxygenated steroids, e. g., the cardioactive compound ouabain and the antitumor compound, rhodexin A. We have several collaborative programs in medicinal chemistry, e.g., to prepare various naturally occurring oxidation products of arachidonic acids, the epoxy isoprostanes (which are involved in the onset of atherosclerosis); to develop a new method of delivering antibacterial agents to resistant bacterial strains; the preparation and testing of new selective binders for both the estrogen and the androgen receptors as anti-cancer agents; the synthesis of molecules which differentiate stem cells into osteoblasts; the preparation of molecules to bind to the Sortase-A binding pocket to determine the structure of this important medicinal target; small molecule inhibitors of the growth of various viruses; agents to stop the growth of tuberculosis; new compounds which induce readthrough of nonsense mutations; and small molecule radioprotective agents.




OTHER PUBLICATIONS


1.  M. E. Jung, "An Improved Procedure for the Conversion of Amines to Alcohols at Low Temperature; New Synthesis of Alkenes and Alkynes from Amines," Chemtracts 1990, 3, 392.

 

2.  M. E. Jung, "Iodomethyl Methyl Ether," Encyclopedia of Reagents for Organic Synthesis, John Wiley & Sons, Ltd., 1995.

 

3.  M. E. Jung, "Trimethylsilyl iodide," Encyclopedia of Reagents for Organic Synthesis, John Wiley & Sons, Ltd., 1995.

 

4.  M. E. Jung, "1-Trimethylsilyloxy-1,3-butadiene," Encyclopedia of Reagents for Organic Synthesis, John Wiley & Sons, Ltd., 1995.

 

5.  M. E. Jung, "2-Trimethylsilyloxy-1,3-butadiene," Encyclopedia of Reagents for Organic Synthesis, John Wiley & Sons, Ltd., 1995.

 

6.  M. E. Jung, "Triphenylcarbenium Tetrafluoroborate," Encyclopedia of Reagents for Organic Synthesis, John Wiley & Sons, Ltd., 1995.

 

7.  W. J. Wechter, E. D. Murray, Jr., D. Kantoci, and M. E. Jung, "Characterization of Two New Endogenous Natriuretic Factors," Abstract, 29th Annual Meeting, American Society of Neurology, November 1996.

 

8.  Crostic No. 49 in Crostics, No. 115, Simon & Schuster, New York, NY, ed. T. H. Middleton, 1996.

 

9.  S. E. Denmark, M. E. Jung, A. Pfaltz, B. Giese, "Laudio for Professor Doctor Albert Eschenmoser," Synlett 1999, III.

 

10.  M. E. Jung, "Tungsten Hexachloride," Encyclopedia of Reagents for Organic Synthesis, John Wiley & Sons, Ltd., 2006.




MEETING ABSTRACTS

1. Richardson, J. A.; Amantea, C. M.; Nguyen, K.; Jung, M. E.; Hahn, T. J.; Parhami, F. "Characterization of osteogenic oxysterols and their molecular mechanism(s) of action,"  J. Bone Mineral Res. 2005, 20, S414-S415 Suppl. 1.

2. Wechter, W. J.; Murray, E. D.; Kantoci, D.; Jung, M. E. "Characterization of two new endogenous natriuretic factors,"  J. Am. Soc. Nephrol. 1996, 7, A2867-A2867.


 

 

SHORT COURSES

 

1.  Nov. 1980:    Upjohn Co., Kalamazoo, MI, "New Advances in the Use of Diels-Alder Reactions in Synthesis."

 

2.  Sept. 1985:    American Cyanamid Co., Agricultural Research Division, Princeton, NJ, "Silicon in Organic Synthesis."

 

3.  Sept. 1987:    Zhongshan University, Guangzhou, PRC, "Modern Organic Synthesis."

 

4.  Sept. 1987:    Zhongshan University, Guangzhou, PRC, "Silicon in Organic Synthesis."

 

5.  April 1996:    3M, St. Paul, MN, "Strategy and Design in Organic Synthesis."

 

6.  April 1998:    3M, St. Paul, MN, "New Methods in Heterocyclic Chemistry."

 

7.  Dec. 1999:    Neurocrine Biosciences, "Introduction to Modern Heterocyclic Chemistry."

 

8.  Mar. 2003:    Université Pierre et Marie Curie, Paris, "Modern Heterocyclic Chemistry."


9.  May 2008:    Vertex, Inc., San Diego, "Modern Heterocyclic Chemistry."


 


PATENTS AND APPLICATIONS


1.  Cross, B.; Los, M.; Doehner, R. F., Jr.; Ladner, D. W.; Johnson, J. L.; Jung, M. E.; Kamhi, V. M.; Tseng, S. S.; Finn, J. M.; Wepplo, P. J. (Assignee:  American Cyanamid Company) "Preparation of Novel Fused Imidazolinylpyridines as Herbicides,"� Eur. Pat. Appl. 1987, EP  227932 A1.


2. Jung, M. E.; Gardiner, J. M. (Assignee:  The Regents of the University of California) "Process for the Synthesis of
2',3'-Dideoxynucleosides," US Patent 5,220,003 (June 15, 1993).

3. Cross, B.; Los, M.; Doehner, R. J., Jr.; Ladner, D. W.; Johnson, J. L.; Jung, M. E.; Kamhi, V. M.; Tseng, S.-S.; Finn, J. M.; Wepplo, P. J. (Assignee:  American Cyanamid Company) "(2-Imidazolin-2-yl) Fused Heteropyridine Compounds, Intermediates for the Preparation of and Use of Said Compounds as Herbicidal Agents," US Patent 5,252,538 (October 12, 1993).
 

4.  Harrington, P. E.; Jung, M. E. (Assignee:  American Cyanamid Company) "Stereoselective Bromination of β-Ribofuranosyl Amide:  Synthesis of Herbicidal Analogues of Hydantocidin,"  US Patent 5,354,868 (October 11, 1994).

 

5.  Jung, M. E.; D'Amico, D. C. (Assignee:  The Regents of the University of California) "Stereospecific Synthesis of Aldols," US Patent 5,426,206 (June 20, 1995).

6.  Harrington, P. E.; Jung, M. E. (Assignee:  American Cyanamid Company) "Process and Intermediates for the Preparation of (+)-Hydantocidin and Analogs Thereof ," US Patent 5,543,510 (August 6, 1996).

 

7.  Jung, M. E.; Cook, P. D.; Kawasaki, A. M. (Assignee:  Isis Pharmaceuticals) "Method for Removing Unreacted Electrophiles from a Reaction Mixture," US Patent 5,632,898 (May 27, 1997).


8.  Fraser, A. S.; Manoharan, M.; Cook, P. D.; Jung, M. E.; Kawasaki, A. M. (Assignee:  Isis Pharmaceuticals) "Alkylation of Alcohols, Amines, Thiols and Their Derivatives by Cyclic Sulfate Intermediates," US Patent 6,277,982 (August 21, 2001).

 

9.  Manoharan, M.; Guzaev, A.; Jung, M. E.; Just, G.; Roland, A.; Wang, J. (Assignee:  Isis Pharmaceuticals) "Oligonucleotides having Alkylphosphonate Linkages and Methods for Their Preparation," US Patent 6,486,313 (November 26, 2002).


10.  Jung, M. E.; Xu, Y. (Assignee:  The Regents of the University of California) "Process for the Synthesis of L-Ribose and 2-Deoxy-L-Ribose," PCT Int. Appl. (1998), WO 9839347 A2 19980911.


11Manoharan, M.; Just, G.; Guzaev, A.; Roland, A.; Wang, J.; Jung, M. E. (Assignee:  Isis Pharmaceuticals) "Solid Phase Synthesis of Alkylphosphonate-linked Oligodeoxyribonucleotides," PCT Int. Appl. (2000), WO2000049032 A1 20000824.


12.  Finn, J.; Morytko, M.; Parr, I. B.; Jung, M. E. (Assignee:  Cubist Pharmaceuticals) "Preparation of novel depsipeptides as antibacterials," PCT Int. Appl. (2003), WO200314147 A1 20030220.


13Morytko, M.; Zhang, Y.; Jung, M. E.; Finn, J.; Bouchard, M. (Assignee:  Cubist Pharmaceuticals) "Preparation of lipopeptide stereoisomeric compounds as antibacterial agents," PCT Int. Appl. (2003), WO200317924 A2 20030306.


14.  Jung, M. E.; Ouk, S.; Sawyers, C. L.; Chen, C. D.; Welsbie, D. (Assignee:  The Regents of the University of California) "Preparation and Activity of Novel Prostate Cancer Drugs," US Provisional Patent Appl., G&C 30435.158-US-P1, Feb. 24, 2004.


15Sawyers, C. L.; Jung, M. E.; Chen, C. D.; Ouk, S.; Welsbie, D. (Assignee:  The Regents of the University of California) "Novel Androgen Receptor Inhibitors with Minimal Agonistic Activities," US Provisional Patent Application, 60/680,835, May 11, 2005.


16.  Manoharan, M.; Jung, M. E.; Rajeev, K. G.; Pandey, R. K.; Wang, G. (Assignee:  Alnylam Pharmaceuticals) "Processes and Reagents for Oligonucleotide Synthesis and Purification," US Provisional Patent Application, 11/099,430, April 5, 2005.


17Whitten, J. P.; Pierre, F.; Regan, C.; Schwaebe, M.; Yiannikouros, G. P.; Jung, M. E. (Assignee:  Cylene Pharmaceuticals) "Novel Benzothiazole Compounds and methods of Use Thereof," US Provisional Patent Application, 11/149,007, June 9, 2005. U.S. Pat. Appl. Publ. 2006, US 2006063761.


18.  Manoharan, M.; Jung, M. E.; Rajeev, K. G.; Pandey, R. K.; Wang, G. (Assignee:  Alnylam Pharmaceuticals) "Process and phosphoramidation reagents for oligonucleotide synthesis and purification," PCT Int. Appl. 2005, WO 2005097817 A2 20051020.


19Jung, M. E.; Ouk, S.; Sawyers, C. L.; Chen, C. D.; Welsbie, D. (Assignee:  The Regents of the University of California) "Androgen receptor-based methods and materials for assessing prostate cancer therapies, and compounds," PCT Int. Appl. (2005), WO 2005099693 A2 20051027.


20.  Whitten, J. P.; Pierre, F.; Regan, C.; Schwaebe, M.; Yiannikouros, G. P.; Jung, M. E., Nagasawa, J. Y.; Chua, P. (Assignee:  Cylene Pharmaceuticals) "Process for the Preparation of Benzothiazole and Phenoxazine Compounds," US Patent Application 2006063761 A1 20060323.


21Whitten, J. P.; Pierre, F.; Regan, C.; Schwaebe, M.; Yiannikouros, G. P.; Jung, M. E. (Assignee:  Cylene Pharmaceuticals) "Preparation of fused quinolone analogs which inhibit cell proliferation and/or induce cell apoptosis," PCT Int. Appl., 2006, WO 2006034113 A2 20060330.


22.  Whitten, J. P.; Pierre, F.; Regan, C.; Schwaebe, M.; Yiannikouros, G. P.; Jung, M. E. (Assignee:  Cylene Pharmaceuticals) "Preparation of fused quinolone analogs which inhibit cell proliferation and/or induce cell apoptosis," US Provisional Patent Application, 2006, US 2006074089, Cont.-in-part of U.S. Ser. No. 149,007. 


23Parhami, F.; Jung, M. E.; Nguyen, K.; Dwyer, J. R. (Assignee:  The Regents of the University of California) "Synthesis and Regulation of Oxysterols," US Provisional Patent Application, Docket No. 38586-347, February 27, 2006.


24.  Sawyers, C. L.; Jung, M. E.; Chen, C. D.; Ouk, S.; Welsbie, D.; Tran, C.; Wongvipat, J.; Yoo, D. (Assignee:  The Regents of the University of California) "Preparation of  Diarylthiohydantoin Compounds as Androgen Receptor Antagonists Useful against Hormone Refractory Prostate Cancer," PCT International Application 2006, WO 2006124118 A1 20061123.


25Parhami, F.; Jung, M. E.; Dwyer, J. R.; Nguyen, K. (Assignee:  The Regents of the University of California) "Preparation of oxysterol compounds that stimulate the hedgehog pathway for treatment of various disorders," PCT International Application 2007, 83 pp. WO 2007098281 A2 20070830.


26.  Jung, M. E.; Yoo, D.; Sawyers, C. L.; Tran, C. (Assignee:  The Regents of the University of California) "Diarylthiohydantoin Compounds," US Patent Application Publication, US 2007254933 A1 20071101.


27Jung, M. E.; Sawyers, Charles L.; Ouk, S.; Tran, C.; Wongvipat, J. (Assignee:  The Regents of the University of California) "Androgen Receptor Modulator for the Treatment of Prostate Cancer and Androgen Receptor-associated Diseases," PCT Int. Appl. (2007), WO 2007126765 A2 20071108.

28. Jung, M. E.; Yoo, D.; Sawyers, C. L.; Tran, C. "Diarylhydantoin derivatives as androgen receptor inhibitors and their preparation, pharmaceutical compositions and use in the treatment of hormone refractory prostate cancer," PCT Int. Appl. (2009), WO 2009055053 A2 20090430.


29. Parhami, F.; Jung, M. E.; Nguyen, K.; Yoo, D.; Kim, W.-K. “Oxysterols for activation of Hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling,” PCT Int. Appl. (2009), WO 2009073186 A1 20090611.


30. Lee, B; Jung, M. E.; Wolf, M. C.; Zhang, T. “Novel Antiviral Agents for Enveloped Viruses,” PCT Int. Appl. (2009), US2009/047854.

31. Bradley, P. J.; Lee, B; Hajagos, B. E.; Wolf, M. C.; Jung, M. E.; Zhang, T. “Rhodanine Derivatives as Broad-spectrum Anti-parasitic Agents,” PCT Int. Appl. (2009), 61218332.



 

INVITED LECTURES

 

496 Lectures, seminars, and presentations at international and national chemical meetings and symposia, academic institutions, and industrial institutions from 1973-2009.